Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Colorcon
McKesson
Baxter
AstraZeneca

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NAMENDA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Namenda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00120874 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed Fisher Center for Alzheimer's Research Foundation Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed Forest Laboratories Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed New York University School of Medicine Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00181298 Memantine in Systemic Lupus Erythematosus Completed Forest Laboratories N/A 2006-03-01 Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.
NCT00181298 Memantine in Systemic Lupus Erythematosus Completed Johns Hopkins University N/A 2006-03-01 Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.
NCT00183729 Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults Completed National Institute of Mental Health (NIMH) Phase 4 2005-08-01 This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or cardiopulmonary condition.
NCT00183729 Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults Completed University of Pittsburgh Phase 4 2005-08-01 This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or cardiopulmonary condition.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Namenda

Condition Name

Condition Name for Namenda
Intervention Trials
Alzheimer's Disease 6
Autism Spectrum Disorder 4
Autism 4
Pediatric Autism 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Namenda
Intervention Trials
Disease 10
Autistic Disorder 8
Autism Spectrum Disorder 7
Alzheimer Disease 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Namenda

Trials by Country

Trials by Country for Namenda
Location Trials
United States 159
Korea, Republic of 4
Spain 4
Canada 3
Colombia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Namenda
Location Trials
New York 14
Massachusetts 13
California 11
Texas 7
Maryland 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Namenda

Clinical Trial Phase

Clinical Trial Phase for Namenda
Clinical Trial Phase Trials
Phase 4 19
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Namenda
Clinical Trial Phase Trials
Completed 33
Recruiting 8
Unknown status 5
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Namenda

Sponsor Name

Sponsor Name for Namenda
Sponsor Trials
Forest Laboratories 23
Massachusetts General Hospital 6
University of Rochester 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Namenda
Sponsor Trials
Other 66
Industry 26
NIH 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Mallinckrodt
Medtronic
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.